This phenomenon may account for the notable decrease in levels of IL-6 and IL-17 in COVID-19 patients experiencing GI symptoms, resulting in reduced mortality rates compared to COVID-19 patients lacking these symptoms. Here, IL6 is linked to COVID-19.